These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
460 related articles for article (PubMed ID: 35131656)
1. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir. Negru PA; Radu AF; Vesa CM; Behl T; Abdel-Daim MM; Nechifor AC; Endres L; Stoicescu M; Pasca B; Tit DM; Bungau SG Biomed Pharmacother; 2022 Mar; 147():112700. PubMed ID: 35131656 [TBL] [Abstract][Full Text] [Related]
2. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options. Sreekanth Reddy O; Lai WF Chembiochem; 2021 Mar; 22(6):939-948. PubMed ID: 33031623 [TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19. Shahrbaf MA; Tabary M; Khaheshi I Cardiovasc Hematol Disord Drug Targets; 2021; 21(2):88-90. PubMed ID: 34387172 [TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. Lai CC; Chao CM; Hsueh PR J Microbiol Immunol Infect; 2021 Oct; 54(5):767-775. PubMed ID: 34253490 [TBL] [Abstract][Full Text] [Related]
5. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. Simonis A; Theobald SJ; Fätkenheuer G; Rybniker J; Malin JJ EMBO Mol Med; 2021 Jan; 13(1):e13105. PubMed ID: 33015938 [TBL] [Abstract][Full Text] [Related]
6. An effective drug against COVID-19: reality or dream? Yaghoubi A; Amel Jamehdar S; Movaqar A; Milani N; Soleimanpour S Expert Rev Respir Med; 2021 Apr; 15(4):505-518. PubMed ID: 33215942 [No Abstract] [Full Text] [Related]
8. COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine. Guan W; Lan W; Zhang J; Zhao S; Ou J; Wu X; Yan Y; Wu J; Zhang Q Virol Sin; 2020 Dec; 35(6):685-698. PubMed ID: 32997322 [TBL] [Abstract][Full Text] [Related]
9. Comparison of remdesivir and favipiravir - the anti-Covid-19 agents mimicking purine RNA constituents. Al-Ardhi FM; Novotny L; Alhunayan A; Al-Tannak NF Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Mar; 166(1):12-20. PubMed ID: 34782799 [TBL] [Abstract][Full Text] [Related]
10. Clinical Trials of Repurposed Antivirals for SARS-CoV-2. Martinez MA Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826 [TBL] [Abstract][Full Text] [Related]
11. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment. Khazir J; Maqbool T; Mir BA Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800 [TBL] [Abstract][Full Text] [Related]
12. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. Wang D; Li Z; Liu Y J Infect Public Health; 2020 Oct; 13(10):1405-1414. PubMed ID: 32684351 [TBL] [Abstract][Full Text] [Related]
13. Emerging treatment strategies for COVID-19 infection. Gavriatopoulou M; Ntanasis-Stathopoulos I; Korompoki E; Fotiou D; Migkou M; Tzanninis IG; Psaltopoulou T; Kastritis E; Terpos E; Dimopoulos MA Clin Exp Med; 2021 May; 21(2):167-179. PubMed ID: 33128197 [TBL] [Abstract][Full Text] [Related]
14. Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far. Saini M; Rana M; Bhatti K; Das R; Mehta DK; Chidurala RM Curr Drug Res Rev; 2022; 14(1):11-19. PubMed ID: 34365935 [TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus. Costanzo M; De Giglio MAR; Roviello GN Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571 [TBL] [Abstract][Full Text] [Related]
16. Can the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insights. Parlak C; Alver Ö; Ouma CNM; Rhyman L; Ramasami P Drug Res (Stuttg); 2022 Jan; 72(1):34-40. PubMed ID: 34535038 [TBL] [Abstract][Full Text] [Related]
17. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Kaptein SJF; Jacobs S; Langendries L; Seldeslachts L; Ter Horst S; Liesenborghs L; Hens B; Vergote V; Heylen E; Barthelemy K; Maas E; De Keyzer C; Bervoets L; Rymenants J; Van Buyten T; Zhang X; Abdelnabi R; Pang J; Williams R; Thibaut HJ; Dallmeier K; Boudewijns R; Wouters J; Augustijns P; Verougstraete N; Cawthorne C; Breuer J; Solas C; Weynand B; Annaert P; Spriet I; Vande Velde G; Neyts J; Rocha-Pereira J; Delang L Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26955-26965. PubMed ID: 33037151 [TBL] [Abstract][Full Text] [Related]
18. Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models. Wang Y; Li P; Rajpoot S; Saqib U; Yu P; Li Y; Li Y; Ma Z; Baig MS; Pan Q Sci Rep; 2021 Dec; 11(1):23465. PubMed ID: 34873274 [TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacodynamics of obeldesivir versus remdesivir. Faghihi I; Yan VC Antimicrob Agents Chemother; 2024 Sep; 68(9):e0096924. PubMed ID: 39133123 [No Abstract] [Full Text] [Related]
20. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]